25 hasil untuk "Jake Shortt"
Menampilkan 1–20 · 0,21 detik · RSS
-
Artikel Jurnal
Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy
Purpose: To determine the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in the setting of optic disc edema secondary to hematologic malignancies. Observations: The report features two patients (one male, one female) in their 70's with biopsy proven hematologic malignancies…
-
Artikel Jurnal
Changes in immune cell populations following KappaMab, lenalidomide and low‐dose dexamethasone treatment in multiple myeloma
Abstract Objectives Lenalidomide (LEN) is used to treat multiple myeloma (MM) and shows in vitro synergy with KappaMab (KM), a chimeric antibody specific for Kappa Myeloma antigen, an antigen exclusively expressed on the surface of kappa‐restricted MM cells. Lenalidomide, dexamethasone (DEX) and KM…
-
Artikel Jurnal Teks lengkap
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma
BACKGROUND: N-methyl-2-pyrrolidone (NMP) is an epigenetically active chemical fragment and organic solvent with numerous applications including use as a drug-delivery vehicle. Previously considered biologically inert, NMP demonstrates immunomodulatory and anti-myeloma properties that are partly…
Juga tersedia di: DOAJ
-
Artikel Jurnal
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse
ABSTRACT Background Next generation sequencing (NGS) of cell free tumour DNA (ctDNA) provides a snapshot of lymphoma mutations correlating with tumour burden. We evaluated the ability of ctDNA to molecularly profile and track disease burden in patients with aggressive‐B‐cell lymphoma. Methods…
-
Artikel Jurnal
Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough?
Although essential in the management of AML, there is little information quantitating transfusion requirements for these patients. We evaluated 111 consecutive adults treated for AML, showing that approximately 150 blood donors are required to adequately cater for a single patient’s complete…
-
Artikel Jurnal
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
Abstract Background In primary central nervous system lymphoma (PCNSL), venous thromboembolism (VTE) can cause significant morbidity and hinder chemotherapy delivery. Objectives To assess VTE incidence, timing and adequacy of inpatient and outpatient VTE prophylaxis in patients with PCNSL receiving…
-
Artikel Jurnal
Bortezomib-based antibody depletion for refractory autoimmune hematological diseases
Abstract: Certain patients with antibody-mediated autoimmune disease exhibit poor responses to conventional immunosuppression, including B-cell depletion with rituximab. Proteasome inhibitors such as bortezomib demonstrate pleiotropic immunomodulatory effects, including direct toxicity to…
-
Artikel Jurnal
Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus
Abstract Background Effective antiviral therapy is lacking for most viral infections, and when available, is frequently compromised by the selection of resistance. Targeted protein degraders could provide an avenue to more effective antivirals, able to overcome the selection of resistance. The aim…
-
Artikel Jurnal
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
Summary: BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evaluated as anti-cancer agents. We find that maximal therapeutic effects of BETi in a Myc-driven B cell lymphoma model required an intact host immune system. Genome-wide analysis of the BETi-induced…
-
Artikel Jurnal
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial
Abstract: Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffective in DLBCL/FL; however, evidence suggests synergy…
-
Artikel Jurnal
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia
Abstract: Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) in chronic phase chronic myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural effusions and pulmonary hypertension, and…